JP2004521911A - 投薬方式 - Google Patents

投薬方式 Download PDF

Info

Publication number
JP2004521911A
JP2004521911A JP2002565625A JP2002565625A JP2004521911A JP 2004521911 A JP2004521911 A JP 2004521911A JP 2002565625 A JP2002565625 A JP 2002565625A JP 2002565625 A JP2002565625 A JP 2002565625A JP 2004521911 A JP2004521911 A JP 2004521911A
Authority
JP
Japan
Prior art keywords
albumin
peptide
fatty acid
solution
exogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002565625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521911A5 (enExample
Inventor
ジュリアーノ シリガーディ
ロアナ フセイン
Original Assignee
キングズ カレッジ ロンドン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キングズ カレッジ ロンドン filed Critical キングズ カレッジ ロンドン
Publication of JP2004521911A publication Critical patent/JP2004521911A/ja
Publication of JP2004521911A5 publication Critical patent/JP2004521911A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2002565625A 2001-02-16 2002-02-15 投薬方式 Pending JP2004521911A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103877.7A GB0103877D0 (en) 2001-02-16 2001-02-16 Novel Drug Delivery system
PCT/GB2002/000680 WO2002066067A2 (en) 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides

Publications (2)

Publication Number Publication Date
JP2004521911A true JP2004521911A (ja) 2004-07-22
JP2004521911A5 JP2004521911A5 (enExample) 2005-06-02

Family

ID=9908913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002565625A Pending JP2004521911A (ja) 2001-02-16 2002-02-15 投薬方式

Country Status (7)

Country Link
US (1) US20040110678A1 (enExample)
EP (1) EP1359941A2 (enExample)
JP (1) JP2004521911A (enExample)
AU (1) AU2002229994A1 (enExample)
CA (1) CA2476397A1 (enExample)
GB (1) GB0103877D0 (enExample)
WO (1) WO2002066067A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518630A (ja) * 2009-02-24 2012-08-16 ヒールオア・リミテッド 挫瘡およびその他の状態を治療するためのビスファチン治療薬
JP2014501262A (ja) * 2010-12-22 2014-01-20 バクスター・インターナショナル・インコーポレイテッド 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
JP2016510017A (ja) * 2013-02-28 2016-04-04 ラボラトワール テア エスアーエス 局所性抗菌皮膚用組成物
JP2018524265A (ja) * 2015-05-08 2018-08-30 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
WO2008128251A1 (en) * 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
EP2653166A3 (en) * 2007-07-30 2014-08-27 Healor Ltd. Pharmaceutical composition and related methods
WO2011083483A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
AT509192B1 (de) * 2010-06-24 2011-07-15 Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems Sorptionsmittel für endotoxine
WO2015136311A1 (en) * 2014-03-13 2015-09-17 The Secretary Of State For Health Antimicrobial conjugates, method for production and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
CA2267179A1 (en) * 1996-09-26 1998-04-02 The University Of Southern California Methods and compositions for lipidization of hydrophilic molecules
WO2000033884A1 (en) * 1998-12-04 2000-06-15 Oregon Health Sciences University Conjugates of lipids and antimicrobial or antineoplastic drugs
CA2375502A1 (en) * 1999-06-23 2000-12-28 The Wistar Institute Of Anatomy & Biology Novel pyrrhocoricin-derived peptides, and methods of use thereof
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518630A (ja) * 2009-02-24 2012-08-16 ヒールオア・リミテッド 挫瘡およびその他の状態を治療するためのビスファチン治療薬
JP2015051973A (ja) * 2009-02-24 2015-03-19 アラヴァ・バイオ‐テック・リミテッドＡｒａｖａ Ｂｉｏ‐Ｔｅｃｈ Ｌｔｄ． 挫瘡およびその他の状態を治療するためのビスファチン治療薬
JP2016183147A (ja) * 2009-02-24 2016-10-20 アラヴァ・バイオ‐テック・リミテッドＡｒａｖａ Ｂｉｏ‐Ｔｅｃｈ Ｌｔｄ． 挫瘡およびその他の状態を治療するためのビスファチン治療薬
JP2014501262A (ja) * 2010-12-22 2014-01-20 バクスター・インターナショナル・インコーポレイテッド 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
JP2016510017A (ja) * 2013-02-28 2016-04-04 ラボラトワール テア エスアーエス 局所性抗菌皮膚用組成物
JP2018524265A (ja) * 2015-05-08 2018-08-30 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法
JP2022033810A (ja) * 2015-05-08 2022-03-02 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法
JP7501918B2 (ja) 2015-05-08 2024-06-18 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法

Also Published As

Publication number Publication date
CA2476397A1 (en) 2002-08-29
AU2002229994A1 (en) 2002-09-04
EP1359941A2 (en) 2003-11-12
GB0103877D0 (en) 2001-04-04
WO2002066067A3 (en) 2003-02-13
WO2002066067A2 (en) 2002-08-29
US20040110678A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
JP5322108B2 (ja) 抗菌ペプチド
E. Greber et al. Antimicrobial peptides under clinical trials
JP5335241B2 (ja) 抗微生物ヘキサペプチド
BR112020019484A2 (pt) Constructos polipeptídicos de lisina-peptídeo antimicrobiano (amp), lisinas, polinucleotídeos isolados codificando as mesmas e seus usos
JP2008514586A (ja) 新規な抗菌剤
JP2001512739A (ja) 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
JP2017526640A (ja) Ｓ．ミュータンス（Ｓ．ｍｕｔａｎｓ）を結合させるターゲティングペプチド、そのようなペプチドを含む構築物、およびその使用
JP2017526640A5 (enExample)
Ahn et al. Discovery of novel histidine-derived lipo-amino acids: applied in the synthesis of ultra-short antimicrobial peptidomimetics having potent antimicrobial activity, salt resistance and protease stability
JP2004521911A (ja) 投薬方式
KR101993937B1 (ko) 염증 억제용 펩티드
JP2023539476A (ja) アネキシンａ１のｎ末端ペプチド製剤及び方法
JP2019513696A (ja) 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
ES2710785T3 (es) Péptidos antimicrobianos basados en CMAP27
US9556228B2 (en) Modified apidaecin derivatives as antibiotic peptides
Shang et al. Engineered peptides harboring cation motifs against multidrug-resistant bacteria
JP2004504017A (ja) 感染症および他の疾患の治療に用いられる、生物活性タンパク質としての新規なヒト・デフェンシンの回収および適用方法
US12409205B2 (en) Nanomolecules for the treatment of inflammatory bowel diseases
Gu et al. A potent antimicrobial glycolipopeptide GLIP and its promising combined antimicrobial effect
Prada et al. New synthetic peptides conjugated to gold nanoclusters: Antibiotic activity against Escherichia coli O157: H7 and methicillin-resistant Staphylococcus aureus (MRSA)
CA3230326A1 (en) Peptides with antimicrobial activities
Li et al. Directed chemical dimerisation enhances the antibacterial activity of the antimicrobial peptide MSI-78 (4–20)
US12214076B2 (en) Drug delivery vehicles for atherosclerosis nanomedicine
WO2009154264A1 (ja) ペプチド
EP2670416B1 (en) A novel high affinity bivalent helically constrained peptide against cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050207

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090624